

Mark R Middleton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7260740/publications.pdf>

Version: 2024-02-01

118
papers

12,321
citations

66343
42
h-index

30922
102
g-index

125
all docs

125
docs citations

125
times ranked

16647
citing authors

#	ARTICLE	IF	CITATIONS
1	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2780-2788.	1.6	1,988
2	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	27.0	1,976
3	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
4	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 1989-2007.	2.8	404
5	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	2.8	345
6	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	2.8	330
7	Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	10.7	330
8	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	2.8	320
9	Phosphatidylinositol 3-Kinase – Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	1.6	298
10	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2010, 46, 270-283.	2.8	284
11	Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2020, 26, 193-199.	30.7	211
12	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	7.1	187
13	Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. <i>Genes and Development</i> , 2017, 31, 18-33.	5.9	184
14	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
15	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
16	Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. <i>Journal of Experimental Medicine</i> , 2010, 207, 491-503.	8.5	170
17	Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1027-1039.	10.7	170
18	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154

#	ARTICLE	IF	CITATIONS
19	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics “ Update 2019. European Journal of Cancer, 2020, 126, 141-158.	2.8	133
20	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 5869-5878.	7.0	131
21	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. European Journal of Cancer, 2020, 128, 60-82.	2.8	131
22	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). European Journal of Cancer, 2019, 114, 117-127.	2.8	120
23	ctDNA monitoring using patient-specific sequencing and integration of variant reads. Science Translational Medicine, 2020, 12, .	12.4	116
24	Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncology, The, 2003, 4, 37-44.	10.7	105
25	Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. Journal of Therapeutic Ultrasound, 2017, 5, 28.	2.2	101
26	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, The, 2014, 15, 620-630.	10.7	96
27	Interferon-Gamma“Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor“Colitis. Gastroenterology, 2021, 161, 1229-1244.e9.	1.3	87
28	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nature Communications, 2016, 7, 11111.	12.8	83
29	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. European Journal of Cancer, 2017, 86, 115-124.	2.8	76
30	First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. European Journal of Cancer, 2019, 109, 103-110.	2.8	76
31	A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 2017, 116, 884-892.	6.4	69
32	Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands. Nature Communications, 2018, 9, 4261.	12.8	65
33	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterology, 2019, 10, 364-371.	1.8	65
34	Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial. Radiology, 2019, 291, 232-238.	7.3	63
35	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS“RAF</i> Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	7.0	60
36	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 510-519.	6.4	59

#	ARTICLE	IF	CITATIONS
37	Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. <i>European Radiology</i> , 2019, 29, 2490-2498.	4.5	58
38	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	1.6	52
39	Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine. <i>Cancer Investigation</i> , 2003, 21, 821-829.	1.3	49
40	Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2897-2907.	7.0	48
41	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018, 29, 1843-1852.	1.2	47
42	Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 185-190.	1.6	43
43	Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 ⁺ T cell clone size and cytotoxicity. <i>Science Immunology</i> , 2021, 6, eabj8825.	11.9	41
44	Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution. <i>Molecular Cell</i> , 2020, 79, 472-487.e10.	9.7	38
45	Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. <i>Developmental Cell</i> , 2021, 56, 2808-2825.e10.	7.0	37
46	Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 262-266.	3.2	36
47	BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. <i>Genes and Development</i> , 2019, 33, 310-332.	5.9	35
48	Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR. <i>Frontiers in Oncology</i> , 2016, 6, 98.	2.8	34
49	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. <i>Cancers</i> , 2019, 11, 70.	3.7	34
50	Safety, pharmacokinetics, and preliminary activity of the $\hat{\pi}$ -specific PI3K inhibitor BYL719: Results from the first-in-human study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2531-2531.	1.6	34
51	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021, 12, 1137.	12.8	33
52	Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes. <i>International Journal of Cancer</i> , 2019, 145, 1125-1137.	5.1	30
53	Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. <i>European Radiology</i> , 2016, 26, 3519-3533.	4.5	27
54	Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 25-38.	2.3	27

#	ARTICLE	IF	CITATIONS
55	Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 266-275.	5.0	27
56	VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 533-543.	7.0	25
57	Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 1776.	3.7	24
58	Dsh Homolog DVL3 Mediates Resistance to IGF1R Inhibition by Regulating IGF-RAS Signaling. <i>Cancer Research</i> , 2014, 74, 5866-5877.	0.9	23
59	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020, 123, 885-897.	6.4	22
60	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
61	Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. <i>British Journal of Cancer</i> , 2021, 124, 1661-1669.	6.4	20
62	IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. <i>Oncotarget</i> , 2015, 6, 39877-39890.	1.8	20
63	A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. <i>Cancer</i> , 2019, 125, 99-108.	4.1	17
64	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. <i>Clinical Cancer Research</i> , 2020, 26, 5709-5719.	7.0	17
65	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. <i>Targeted Oncology</i> , 2016, 11, 557-563.	3.6	16
66	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	6.7	16
67	Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. <i>BMC Health Services Research</i> , 2018, 18, 393.	2.2	15
68	Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. <i>European Journal of Cancer</i> , 2020, 132, 176-186.	2.8	15
69	Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. <i>Cancer Medicine</i> , 2016, 5, 17-23.	2.8	14
70	Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. <i>Cancer Medicine</i> , 2016, 5, 1436-1443.	2.8	14
71	Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. <i>BMC Cancer</i> , 2021, 21, 3.	2.6	14
72	An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22050-e22050.	1.6	14

#	ARTICLE	IF	CITATIONS
73	RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases “ results and lessons learnt. British Journal of Cancer, 2016, 115, 1193-1200.	6.4	13
74	A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).. Journal of Clinical Oncology, 2020, 38, 10022-10022.	1.6	13
75	Quinone Oxidoreductase-2“Mediated Prodrug Cancer Therapy. Science Translational Medicine, 2010, 2, 40ra50.	12.4	11
76	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. British Journal of Cancer, 2018, 119, 793-800.	6.4	11
77	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 2018, 118, 770-776.	6.4	9
78	Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer, 2021, 21, 642.	2.6	9
79	Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. European Radiology, 2019, 29, 6717-6727.	4.5	8
80	A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2019, 37, 406-406.	1.6	8
81	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. European Journal of Cancer, 2021, 158, 225-233.	2.8	8
82	Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. Journal of Clinical Oncology, 2022, 40, 9553-9553.	1.6	8
83	First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2520-2520.	1.6	7
84	VCAM-1“targeted MRI Improves Detection of the Tumor-brain Interface. Clinical Cancer Research, 2022, 28, 2385-2396.	7.0	7
85	Lag3: From Bench to Bedside. Cancer Treatment and Research, 2022, 183, 185-199.	0.5	7
86	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. Journal of Clinical Oncology, 2017, 35, 9501-9501.	1.6	6
87	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. Journal of Clinical Oncology, 2019, 37, 9584-9584.	1.6	6
88	Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT. Chronic Illness, 2023, 19, 81-94.	1.5	6
89	Genetic susceptibility to Barrett’s oesophagus: Lessons from early studies. United European Gastroenterology Journal, 2016, 4, 485-492.	3.8	5
90	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. European Journal of Cancer, 2020, 131, 100-103.	2.8	4
92	Pharmacodynamic effect of IMCgp100 (TCR“CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9523-9523.	1.6	4
93	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. Journal of Clinical Oncology, 2019, 37, 9592-9592.	1.6	4
94	PTU-061“...Immunotherapy-related gastritis in a tertiary oncology centre. , 2019, , .		3
95	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq1 1 0.784314 rgBT /Overdo activation. Cancer Research, 2021, 81, LB180-LB180.	0.9	3
96	Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR“anti-CD3, in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9530-9530.	1.6	3
97	DETECTION phase II/III trial: Circulating tumor DNA“guided therapy for stage IIB/C melanoma after surgical resection.. Journal of Clinical Oncology, 2022, 40, TPS9603-TPS9603.	1.6	3
98	A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. BMC Cancer, 2021, 21, 851.	2.6	2
99	A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5565-5565.	1.6	2
100	An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS2671-TPS2671.	1.6	2
101	Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer. Radiology Case Reports, 2018, 13, 1259-1266.	0.6	1
102	Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?. Lancet Oncology, The, 2018, 19, 1424-1426.	10.7	1
103	Response to: Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. European Journal of Cancer, 2020, 140, 154-157.	2.8	1
104	Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics. Journal of Thoracic Disease, 2017, 9, 3551-3552.	1.4	0
105	Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.. Journal of Clinical Oncology, 2021, 39, 309-309.	1.6	0
106	Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.. Journal of Clinical Oncology, 2013, 31, e15061-e15061.	1.6	0
107	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	0
108	Real-world overall survival in advanced melanoma from the IMAGE study.. Journal of Clinical Oncology, 2016, 34, 9531-9531.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).. Journal of Clinical Oncology, 2019, 37, 9568-9568.	1.6	0
110	506â€¦IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. , 2021, 9, A538-A538.		0
111	CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, CGE22-097.	4.9	0
112	Cancer of the Colon and Rectum. , 0, , 325-373.		0
113	Abstract 1247: Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma. Cancer Research, 2022, 82, 1247-1247.	0.9	0
114	A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and nonâ€œsmall cell lung cancer (NSCLC; IMP-MEL).. Journal of Clinical Oncology, 2022, 40, 2582-2582.	1.6	0
115	Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation. Cancer Research, 2022, 82, CT155-CT155.	0.9	0
116	A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS2704-TPS2704.	1.6	0
117	An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS2705-TPS2705.	1.6	0
118	ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9609-TPS9609.	1.6	0